Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit
satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation …

Abstract Alzheimer's disease (AD), a progressive neurodegenerative disorder, is
characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in …

Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's
diseases), and of malignancy (cancers) have complex and varied causative factors. Modern …

With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes
an overwhelming health, social, economic, and political problem to nations. Unless a new …

During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

Multifunctional compounds (MFCs) are designed broadly as hybrid or conjugated drugs or
as chimeric drugs from two or more pharmacophores/drugs having specific pharmacological …

Alzheimerβs disease (AD) is a multifactorial neurodegenerative disorder with several target
proteins contributing to its aetiology. Pathological, genetic, biochemical, and modeling …

By using fragments endowed with interesting and complementary properties for the
treatment of Alzheimer's disease (AD), a new family of tacrine–4-oxo-4 H-chromene hybrids …

Tacrine and PBT2 (an 8-hydroxyquinoline derivative) are well-known drugs that inhibit
cholinesterases and decrease β-amyloid (Aβ) levels by complexation of redox-active metals …

Alzheimer's disease (AD) is a genetically complex, progressive and irreversible
neurodegenerative disorder of the brain which involves multiple associated etiological …